Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?

被引：0

作者：

P. Ivanyi

T. Park-Simon

H. Christiansen

R. Gutzmer

A. Vogel

M. Heuser

H. Golpon

P. Hillemanns

J. Haier

机构：

[1] Hannover Medical School,Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation

[2] Hannover Medical School,Department of Gynecology and Obsterics

[3] Hannover Medical School,Department of Radiotherapy and Special Oncology

[4] Hannover Medical School,Department of Dermatology and Allergy, Skin Cancer Center Hannover

[5] Hannover Medical School,Department of Gastroenterology, Hepatology and Endocrinology

[6] Hannover Medical School,Department of Pulmonology, Medizinische Hochschule Hannover

[7] Comprehensive Cancer Center Niedersachsen (CCC-N),undefined

[8] Hannover Medical School,undefined

[9] Immuncooperative Oncology Group (ICOG) of CCC-N,undefined

[10] Hannover Medical School,undefined

来源：

Clinical & Experimental Metastasis | 2021年 / 38卷

关键词：

Sars-CoV-19; COVID-19; Metastasis; Treatment; Cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Cancer patients represent a vulnerable cohort during the Sars-CoV-2 pandemic. Oncological societies have generated a plethora of recommendations, but precise instructions about routine oncological procedures remain scarce. Here, we report on local COVID-19 protection measures established in an interdisciplinary approach at a tertiary care center during the first wave of the pandemia in Germany. Following these measures, no additional morbidity or mortality during oncological procedures was observed, and no nosocomial infections were registered. However, Validation of our measures is outstanding and regional SARS-CoV-2 prevalence was low. However, specific oncological measures might be important to ensure optimal oncological results, especially for advanced cancer stages during this and future pandemia. In the future, communication about these measures might be crucial to a cancer patient´s assigned network to reduce the danger of excess mortality within the second wave of the COVID-19 pandemic.

引用

页码：257 / 261

页数：4

共 55 条

[1]

Hanna TP(2020)Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic Nat Rev Clin Oncol 17 268-270

[2]

Evans GA(2020)Cancer Patient Care during COVID-19 Cancer Cell 37 749-750

[3]

Booth CM(2020)Comment Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer : the view from primary care Lancet Oncol 2045 19-20

[4]

Harky A(2020)COVID-19 and cancer: what we know so far Nat Rev Clin Oncol 17 336-901

[5]

Chiu CM(2020)Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Ann Oncol 31 894-212

[6]

Yau THL(2016)Community acquired respiratory virus infections in cancer patients—Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology Eur J Cancer 67 200-337

[7]

Lai SHD(2020)Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Lancet Oncol 21 335-1242

[8]

Jones D(2020)Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention JAMA - J Am Med Assoc 323 1239-1720

[9]

Neal RD(2020)Clinical Characteristics of Coronavirus Disease 2019 in China N Engl J Med 382 1708-4633

[10]

Duffy SRG(2012)A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: Early therapy improves outcomes Cancer 118 4627-1056

← 1 2 3 4 5 6 →